INTEGRATED BIOPHARMA INC

None.

-29-

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

. . . . . . . . .

-30-

To the Stockholders and Board of Directors of

Integrated BioPharma, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Integrated BioPharma, Inc. (the “Company”) as of June 30, 2026 and 2025, and the related consolidated statements of operations, stockholders’ equity and cash flows for the two years in the period ended June 30, 2026, and the related notes (collectively referred to as the “financial statements”). In our opinion,** **the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2026, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit** **provides a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

/s/CBIZ CPAs P.C.

CBIZ CPAs P.C.

We have served as the Company’s auditor since 2009.** **

Morristown, New Jersey

September 25, 2026

-31-

-32-

-33-

-34-

-35-

Note1. Business**

Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg. The Company was originally incorporated in the state of Delaware on* August 31, 1995under the name Chem International, Inc., on December 5, 2000,changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003,changed its name to Integrated BioPharma, Inc. The Company restated its certificate of incorporation in Delaware in June 2006.*The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Business Lines which includes the operations of (i) MDC Warehousing and Distribution, Inc. ("MDCWHD"), a service provider for warehousing and fulfillment services, (ii) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. and the holding entity of the Company and (iii) all other inactive subsidiaries of the Company.

Note2. Summary of Significant Accounting Policies**

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation.

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that arenot readily apparent from other sources. The most significant estimates include:

● sales returns and allowances;

● allowance for credit losses;

● inventory valuation;

● income taxes and valuation allowance on deferred income taxes, and;

● accruals for, and the probability of, the outcome of current litigation, if any.

On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

Revenue Recognition. The Company recognizes product sales revenue, the prices of which are fixed and determinable, when title and risk of loss have transferred to the customer, when estimated provisions for product returns, rebates, charge-backs and other sales allowances are reasonably determinable, and when collectability is reasonably assured. Accruals for these items are presented in the consolidated financial statements as reductions to sales. The Company’s net sales represent gross sales invoiced to customers, less certain related charges for discounts, returns, rebates, charge-backs and other allowances. Cost of sales includes the cost of raw materials and all labor and overhead associated with the manufacturing and packaging of the products. Gross margins are affected by, among other things, changes in the relative sales mix among our products and valuation and/or charge off of slow moving, expired or obsolete inventories. The Company also recognizes revenue for warehousing and fulfillment services provided to MDCWH customers.

-36-

To perform revenue recognition for arrangements within the scope of ASC606, the Company performs the followingfive steps:

Shipping and Handling Costs. Shipping and handling costs were approximately $690 and $927 for the fiscal years ended* June 30, 2026and2025,* respectively, and are included in cost of sales in the accompanying Consolidated Statements of Operations.

***Stock-Based Compensation.*The Company hastwo stock-based compensation plans that have outstanding options issued in accordance with such plans. The Company periodically grants stock options to employees and directors in accordance with the provisions of its stock option plans, with the exercise price of the stock options being set at the closing market price of the common stock on the date of grant. Stock based compensation expense is recognized based on the estimated fair value, utilizing a Black-Scholes option pricing model, of the instrument on the date of grant over the requisite vesting period, which is generally three years.

Income Taxes. The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely thannot that all or a portion of a deferred tax asset willnot be realized.

The Company files U.S. federal and New Jersey state income tax returns. The Company’s income taxes havenot been examined by any tax authorities for the periods subject to review by such taxing authorities. Uncertain tax positions, if any, taken on our tax returns are accounted for as liabilities for unrecognized tax benefits. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the Consolidated Statements of Operations. There wereno liabilities recorded for uncertain tax positions at* June 30, 2026or2025.*

***Leases.***We determine if an arrangement is a lease at inception. Operating and finance leases are included in right-of-use (“ROU”) assets, other current liabilities, and lease liabilities on our consolidated balance sheets.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases donot provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms* may*include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.

-37-

***Earnings Per Share.***Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, subject to anti-dilution limitations using the treasury stock method.

***Fair Value of Financial Instruments.*Generally accepted accounting principles require disclosing the fair value of financial instruments to the extent practicable for financial instruments which are recognized or unrecognized in the balance sheet. The fair value of the financial instruments disclosed herein isnot necessarily representative of the amount that could be realized or settled, nor does the fair value amount consider the tax consequences of realization or settlement.

In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value.

Accounts Receivable and Allowance for Credit Losses. In the normal course of business, the Company extends credit to customers. Accounts receivable, less the allowance for credit losses, reflect the net realizable value of receivables, and approximate fair value. The Company believes there isno concentration of credit risk with any single customer whose failure or nonperformance would materially affect the Company’s results other than as discussed in Note9(c) – Significant Risks and Uncertainties – Major Customers. On a regular basis, the Company evaluates its accounts receivables and establishes an allowance for credit losses based on a combination of specific customer circumstances, credit conditions, and historical write-offs and collections. The allowance for credit losses as of* June 30, 2026and2025* was $20. Accounts receivable are charged off against the allowance after management determines that the potential for recovery is remote.

***Inventories.*Inventories are stated at the lower of cost or net realizable value. Cost is determined using thefirst-in,first-out method. Allowances for obsolete and overstock inventories are estimated based on “expiration dating” of inventory and projection of sales.

***Property and Equipment.***Property and equipment are recorded at cost and are depreciated using the straight line method over the following estimated useful lives:

Accounting Pronouncements Adopted

In* December 2023,the FASB issued ASU2023*-09 - Income Taxes (Topic740): Improvements to Income Tax Disclosures, which requires public entities to provide greater disaggregation within their annual rate reconciliation, including new requirements to present reconciling items on a gross basis in specified categories, disclose both percentages and dollar amounts, and disaggregate individual reconciling items by jurisdiction and nature when the effect of the items meet a quantitative threshold. The guidance also requires disaggregating the annual disclosure of income taxes paid, net of refunds received, by federal (national), state, and foreign taxes, with separate presentation of individual jurisdictions that meet a quantitative threshold. The guidance was effective for this annual period beginning* July 1, 2025on a prospective basis, with a retrospective option, with early adoption permitted. The Company has adopted this standard on a retrospective basis and the standard didnot* have a significant impact on its consolidated financial statements and disclosures. See Note7. Income Taxes for the Company’s income tax disclosures.

-38-

Accounting PronouncementsNot Yet Adopted**

In* November 2024,the FASB issued ASU2024*-03 (updated ASU2025-01 issued in* January 2025),Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic220*-40): Disaggregation of Income Statement Expenses, which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the financial statements to provide enhanced transparency into the expense captions presented on the face of the income statement. The guidance is effective for the Company’s annual periods beginning* July 1, 2027,and interim periods thereafter, on a prospective basis, with a retrospective option, and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU2024*-03.

In* July 2025,the FASB issued ASU2025*-05 - Financial Instruments - Credit Losses (Topic326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides for an election for a practical expedient to assume that current conditions as of the balance sheet date donot change for the remaining life of the asset. The update is effective for the Company’s annual periods beginning* July 1, 2027and interim periods thereafter on a prospective basis, with a retrospective option, and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU2025*-05.

In* December 2025,the FASB issued ASU2025*-11 – Interim Reporting (Topic270) Narrow-Scope Improvements, which improves the guidance in Topic270 by improving the navigability of the required interim disclosures and clarifying when the guidance is applicable. The update is effective for the Company’s interim reporting periods beginning after* December 15, 2027and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU2025*-11.

Note3. Inventories**

Inventories are stated at the lower of cost or net realizable value using thefirst-in,first-out method and consist of the following:

Note4. Property and Equipment, net**

Property and equipment consists of the following:

Depreciation and amortization expense was $293 and $318 for the fiscal years ended* June 30, 2026and2025,* respectively. The Company disposed of fully depreciated property of $55 and $61 in the fiscal years ended* June 30, 2026and2025,* respectively. Additionally, in the fiscal year ended* June 30, 2025,the Company transferred a right of use asset in the amount of $112 with a net book value of $80 to machinery and equipment that it acquired upon the payment in full of the related financing obligation. In the fiscal years ended June 30, 2026and2025,* the Company recognized a permanent impairment of $30 and $28 and a gain (loss) on disposal of fixed assets of $6 and $(4), respectively.

-39-

Note5. Lines of Credit**

Loan Agreement

On* June 30, 2026,Integrated BioPharma, Inc. (the "Company") and Manhattan Drug Company, Inc., a wholly owned subsidiary of the Company (collectively, the "Borrower"), entered into an Amendment to Loan Documents (the "First Amendment") with PNC Bank, National Association ("PNC") amending certain loan documents related to the Loan Agreement entered into with PNC dated as of April 15, 2025 (the “Loan Agreement”). The First Amendment extends the expiration date of the existing committed revolving line of credit to April 14, 2027 (the "Expiration Date"). The revolving line of credit continues to provide for advances in an aggregate principal amount outstanding at any timenot* to exceed $4,000. The Borrower also entered into a Convertible Line of Credit Note (Daily SOFR) payable to the order of PNC in an amount in the aggregate at any time outstandingnot to exceed $250 (the "Convertible ELOC"). Advances under the Convertible ELOC will be used for the purchase of equipment and/or vehicles. The First Amendment terminated the Convertible Equipment Line of Credit Note (Daily SOFR), dated as of* April 15, 2025,by the Borrower and payable to the order of PNC Bank in the amountnot* to exceed $500, which had matured and is ofno further force or effect and has been replaced by the Convertible ELOC.

The Loan Agreement provides a committed revolving line of credit under which the Company* mayrequest, and PNC will make advances to the Company from time to time until the Expiration Date, in an aggregate amount outstanding at any timenot* to exceed $4,000.

The Line of Credit bears interest at a rate per annum which is equal to the sum of (A) Dailyone-month SOFR plus (B)250 basis points (2.50%). Accrued interest will be due and payable on the same day of each month, beginning with the payment due on* May 15, 2025.*The outstanding principal balance and any accrued but unpaid interest shall be due and payable on the Expiration Date.

Prior to the conversion date under the Convertible ELOC (the "Conversion Date”), amounts outstanding under the Convertible ELOC will bear interest at a rate per annum (the "Daily Rate”) equal to the sum of (i) dailyone-month SOFR plus (ii)250 basis points (2.50%), and from and after the Conversion Date, amounts outstanding under the Convertible ELOC will bear interest for the remaining term at either (i) a rate per annum equal to the Daily Rate or (ii) a fixed rate of interest per annum as offered to the Borrower by the Bank in its sole discretion and agreed upon in writing between the Borrower and PNC.

As of* June 30, 2026,the Company didnot* meet its Fixed Charge Coverage Ratio, as defined in the Loan Agreement, of 1.10 to1.0 and has requested a waiver from PNC for this default which it expects to receive. As of* June 30, 2026and2025,* the Company hadno debt outstanding under its Lines of Credit.

The Company also entered into a Reimbursement Agreement for Standby and Commercial Letter(s) of Credit whereby, from time to time, the Borrower* mayrequest the issuance ofone* or more letters of credit (each a "Credit"). The Credit bears interest at the same rate as the Line of Credit under the Loan Agreement as described above.

In addition, in connection with the Loan Agreement, the Company and MDC (collectively, the "Grantors") each entered into a Security Agreement with PNC, pursuant to which each of the Grantors assigned and granted to PNC, as secured party, a continuing lien on and security interest in all right, title and interest of such Grantor in, to, and under all of the assets of such Grantor.

-40-

Note6. Interest Expense**

The components of interest expense for the fiscal years ended* June 30, 2026and2025* are presented below:

The weighted average interest rate paid was 0% and 8.01% in the fiscal years ended* June 30, 2026and2025,* respectively. As of* June 30, 2026and2025,* the Company hadno unpaid interest.

Note7. Income Taxes**

The Company’s net (loss) income before income taxes for the fiscal years ended* June 30, 2026and2025* was $(2,563) and $2,062, respectively.

The annual provision (benefit) for income taxes differs from amounts computed by applying the maximum U.S. Federal income tax rate of 21% to pre-tax income as follows:

New Jersey represents substantially all of the state (benefit) income tax above.

The components of the provision for income taxes consists of the following:

The Company files consolidated U.S. federal and combined state of New Jersey income tax returns.

-41

Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial accounting purposes and the amounts used for income tax reporting. Significant components of the Company’s net deferred tax assets are as follows:

The Company has net operating losses (“NOL”) of approximately $21,626 and $19,249 for federal tax purposes for the fiscal years ended* June 30, 2026and2025,* respectively. As of* June 30, 2026,$19,176 of the federal NOL’s expire beginning in2028,* which were federal NOLs generated prior to2018 and $2,450 of NOLs generated post2018 which have an indefinite life, subject to80% of taxable income in each taxable year used. Additionally, as of* June 30, 2026and2025,* the Company has New Jersey state NOL’s of approximately $3,877 and $4,005, respectively, which expire beginning in2031 through2039. The Company also has capital loss carryforwards of $1,191 of which $270 and $920 will expire in2027 and2028, respectively.

Realization of the NOL carryforwards and other deferred tax temporary differences is contingent on future taxable earnings. The Company’s deferred tax asset was reviewed for expected utilization using a “more likely thannot” approach by assessing the available positive and negative evidence surrounding its recoverability. One of the criteria considered in this assessment is the Company’s history of cumulative losses in recent years. Such cumulative losses are considered objective negative evidence under ASC740 and are considered in the realizability analysis. While the current fiscal year ended* June 30, 2026is the Company’sfirst* net operating loss in several years, it did offset the previoustwo years of operating income, resulting in a cumulative loss. Although the Company has cumulative losses for thisthree-year lookback period, the Company isnot anticipating operating losses in subsequent years. This, along with the aging of the NOL’s supports management’s opinion that it is more likely thannot that some of the Company’s NOL’s willnot be utilized in the foreseeable future. Accordingly, in the fiscal years ended* June 30, 2026and2025,* valuation allowances in the amounts of $1,000 and $830 were recorded against the Company’s deferred tax asset relating to its federal NOL, respectively. In the fiscal year ended* June 30, 2025,*the Company released its valuation reserve on its state NOL’s in the amount of $347, as there was a change in the tax regulations that permitted the Company to use NOL’s generated by the combined group to offset current year taxable income for the combined group. Prior years only permitted the entity that generated the NOL to offset against its current taxable income.

The Company will continue to assess and evaluate strategies that will enable the deferred tax asset, or portion thereof, to be utilized, and will reduce the valuation allowance appropriately at such time when it is determined that the “more likely thannot” criteria is satisfied.

The utilization of the Company’s federal NOLs could be subject to Section382 of the Internal Revenue Code of1986, as amended (the “Code”), due to ownership change limitations that* mayhave occurred previously or that could occur in the future. These ownership changes limit the amount of NOLs and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section382* results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than50 percent points over athree-year period. The Company hasnot completed an analysis of an ownership change under Section382 of the Code. To the extent that a study is completed and an ownership change is deemed to occur, the Company’s NOLs could be limited.

-42-

There wereno significant uncertain tax positions taken, or expected to be taken, in a tax return that would be determined to be an unrecognized tax benefit taken or expected to be taken in a tax return that should have been recorded on the Company’s consolidated financial statements for the year ended* June 30, 2026.Additionally, there wereno interest or penalties outstanding as of or for each of the fiscal years ended June 30, 2026and2025.*

The latest three years of Federal andfour years of state tax returns filed for the fiscal years ended through* June 30, 2025are currently open. The tax returns for the year ended June 30, 2026will be filed by March 15, 2027.*

Note8. Profit-Sharing Plan**

The Company maintains a profit-sharing plan, which qualifies under Section401(k) of the Internal Revenue Code, covering all nonunion employees meeting age and service requirements. Contributions are determined by matching a percentage of employee contributions. For the fiscal years ended* June 30, 2026and2025,* the Company contributed approximately $91 and $86, respectively, into the plan for the benefit of the eligible employees participating in the plan.

Note9. Significant Risks and Uncertainties**

***(a) Concentrations of Credit Risk-Cash.**The Company maintains balances at several financial institutions. Deposits at each institution are insured by the Federal Deposit Insurance Corporation up to $250. As of June 30, 2026,*the Company had $4,381 in uninsured deposits at these financial institutions.

(b) Concentrations of Credit Risk-Receivables. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk of its customers, establishes an allowance for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowances is limited. The Company doesnot require collateral in relation to its trade accounts receivable credit risk.

(c) Major Customers.In the fiscal years ended June 30, 2026and2025, approximately 90% and 84% of consolidated net sales, were derived fromtwo customers. Thesetwo customers are in the Company’s Contract Manufacturing Segment and represent approximately 68% and 25% and 62% and 26%, respectively, of this segment’s net sales in the fiscal years ended* June 30, 2026and2025,* respectively. Accounts receivable from thesetwo major customers represented approximately 81% and 76% of total net accounts receivable as of* June 30, 2026and2025,* respectively. The loss of any of these customers could have an adverse effect on the Company’s operations. One andfour customers in the Other Business Lines Segment, whilenot significant customers of the Company’s consolidated net sales, represented approximately 29% and 32%,25%,11% and 10%, respectively, of net sales of the Other Business Lines Segment in the fiscal years ended* June 30, 2026and2025,* respectively. Major customers are those customers who account for more than10% of net sales.

***(d) Business Risks.*The Company insures its business and assets against insurable risks, to the extent that it deems appropriate, based upon an analysis of the relative risks and costs. The Company believes that the risk of loss from non-insurable events wouldnot have a material adverse effect on the Company’s operations as a whole.

The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies.

As of* June 30, 2026,approximately 77% of the Company’s employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed effective September 1, 2022and will expire on September 30, 2026,as extended on July 21, 2026from an original expiration date of August 31, 2026.*

The Company has seen a negative impact in our margins due to inflation, tariffs and to a lesser extent, tightened labor markets as we strive to increase prices to our customers as our operating costs increase. We* may**not* be able to timely increase our selling prices to our customers resulting from price increases from our suppliers due to various economic factors, including tariffs and other inflationary costs, labor and shipping costs and our own increases in shipping, labor and other operating costs. Our results of operations* mayalso be affected by economic conditions, including tariffs and other inflationary pressures, that can impact consumer disposable income levels and spending habits, thereby reducing the orders we may*receive from our significant customers.

-43-

Note10. Lease Commitments and Contingencies**

***(a) Leases.***The Company has operating and finance leases for its corporate and sales offices, warehousing and packaging facilities and certain machinery and equipment, including office equipment. The Company’s leases have remaining terms of less than 1 year to less than 5 years.

The components of lease expense for the fiscal year ended* June 30, 2026and2025* were as follows:

Rent and lease amortization costs are included in cost of sales and selling and administrative expenses in the accompanying Consolidated Statements of Operations.

Operating Lease Liabilities

Related Party Operating Lease Liabilities. Warehouse and office facilities are leased from Vitamin Realty Associates, LLC (“Vitamin Realty”), which is controlled with 41% ownership by each of the Company’s Co-Chief Executive Officers and directors of the Company and 18% by their mother, a major stockholder of the Company. On* January 5, 2012,MDC entered into asecond* amendment to the lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to* January 31, 2026.This Second Lease Amendment provided for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses. On July 15, 2022,MDC entered into athird* amendment to the lease (the “Third Lease Amendment”) with Vitamin Realty, increasing its rentable square footage to 116,175. This Third Lease Amendment provided for minimum annual rental payments of $842, plus increases in real estate taxes and the building operating expenses allocation percentage and is effective as of* July 1, 2022.On February 17, 2026,MDC entered into afourth* amendment of the lease (the “Fourth Lease Amendment”). The Fourth Amendment, decreases the rentable square footage to 110,095, provides for minimum annual rental payments of $1,101 and extended the expiration date to* January 31, 2029.*

Rent expense, lease amortization costs and imputed interest costs on these related party leases were $1,541 and $1,345 for the fiscal years ended* June 30, 2026and2025,* respectively, and are included in cost of sales and selling and administrative expenses in the accompanying Consolidated Statements of Operations. As of* June 30, 2026and2025,* the Company hadno outstanding current obligations to Vitamin Realty. Additionally, as of* June 30, 2026and2025,* the Company has operating lease obligations of $2,720 and $485, respectively, with Vitamin Realty as noted in the accompanying Consolidated Balance Sheet.

On* April 27, 2026,the Company entered into an operating lease with First American Commercial Bancorp, Inc. in the amount of $22 for office equipment with an annual commitment of approximately $5, and an expiration date of April 30, 2031.*

-44-

Other Operating Lease Liabilities. The Company has entered into certain non-cancelable operating lease agreements expiring up through* May 9, 2027,*related to machinery and equipment and office equipment.

As of* June 30, 2026,*the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:

As of* June 30, 2025,*the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:

As of* June 30, 2026and2025,* the Company’s weighted average discount rate is 6.41% and 5.31% for the fiscal years then ended, respectively, and the remaining term on lease liabilities is approximately 2.5 years and 1.4 years, respectively.

Financed Lease Obligation.

As of* June 30, 2026,*the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:

-45-

As of* June 30, 2025,*the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:

As of* June 30, 2026and2025,* the Company’s weighted average discount rate is 6.89% and 4.51% for the fiscal years then ended, respectively, and the remaining term on lease liabilities is approximately 2.5 years and 3.4 years, respectively.

Supplemental cash flows information related to leases for the fiscal year ended* June 30, 2026*is as follows:

Supplemental cash flows information related to leases for the fiscal year ended* June 30, 2025*is as follows:

-46-

Maturities of operating lease liabilities as of* June 30, 2026*were as follows:

(b) Legal Proceedings.

The Company is subject, from time to time, to claims bythird parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

Note11. Related Party Transactions**

Information related to related party transactions are disclosed in Note10(a). Leases for related party lease transactions.

Note12. Equity Transactions and Stock-Based Compensation**

Stock Option Plans. In* December 2025,the Board of Directors adopted the Integrated BioPharma, Inc. Equity Incentive Plan (the“2025* Plan”) which authorized the grants of options or restricted shares to employees, officers, directors and consultants which provides for the issuance of 7,500,000 underlying shares of the Company’s Common Stock at the discretion of the Board of Directors. Prior to the adoption of the Plan, the Company had adopted the2001 Stock Option Plan, as amended (the*“2001* Plan”) and the1997 Stock Option Plan (the*“1997* Plan”) that provided for the issuance of up to 13,000,000 and 5,000,000 shares of common stock, respectively. Stock option grants* may**not* be priced less than the fair market value of the Company’s common stock at the date of grant. Options granted are generally forten-year periods, except that incentive stock options granted to a10% stockholder (as defined) are limited tofive-year terms. As of* June 30, 2026,the Company has 6,773,500 shares of common stock remaining under the2025* Plan. The1997 Plan and2001 Plan were terminated with the adoption of the2025 Plan withno future options to be issued under either plan.

In the fiscal year ended* June 30, 2026,the Board of Directors authorized the issuance of 534,000 stock options to Company officers and employees and 200,000 stock options to the Company’s non-executive directors. The Company issued 526,500 stock options with an exercise price of $0.31 and $0.35, vesting over three years, to the officers and employees,200,000 shares to the non-executive directors (50,000 each) with an exercise price of $0.19 and $0.20, vesting overone year,25% at the end of each quarter ending September 30, 2026,** December 31, 2026,** March 31, 2027and June 30, 2027,*each grant with expiration terms often years from the date of grant.

For the fiscal years ended* June 30, 2026and2025,* the Company incurred stock-based compensation expense of $192 and $185, respectively. The Company expects to record additional stock-based compensation of $239 over the remaining estimated vesting period of approximatelytwo and a half years.

-47-

The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended* June 30, 2026:*

The Company calculates expected volatility for a stock-based grant based on historic daily stock price observations of its common stock during the period immediately preceding the grant that is equal in length to the expected term of the grant. The expected term of the options is estimated based on the Company’s historical exercise rate and forfeiture rates are estimated based on employment termination experience. The risk free interest rate is based on U.S. Treasury yields for securities in effect at the time of grants with terms approximating the term of the grants. The assumptions used in the Black-Scholes option valuation model are highly subjective, and can materially affect the resulting valuations.

In the fiscal year ended* June 30, 2025,*the Board of Directors authorized the issuance of 890,000 stock options to Company officers, employees and directors with exercise prices ranging from $0.18 to $0.34, vesting overone orthree years, with terms often years.

In the fiscal years ended* June 30, 2026and2025,* stock options in the aggregate amount of 5,113,350 and 2,445,850 werenot included in the computation of weighted average diluted common shares outstanding as the effect of doing so would have been anti-dilutive.

The intrinsic value of options outstanding and exercisable as of* June 30, 2026and2025* was $0 and $227, respectively.

A summary of the Company’s stock option activity, and related information for the years ended* June 30,*follows:

-48-

The following table summarizes the range of exercise prices and weighted-average exercise prices for stock options outstanding and exercisable as of* June 30, 2026*under the Company’s stock option plans:

Note13. Segment Information**

In its operation of the business, management, including its chief operating decision makers (“CODMs”), who are also the Company’s Co-Chief Executive Officers, review certain financial information, including segmented internal profit and loss statements. The primary profitability measure used by the CODMs to review segment operating results is gross profit. The CODM uses gross profit to allocate resources during our annual planning process and throughout the year, as well as to assess the performance of the Company’s segments, primarily by monitoring actual results compared to prior periods and expected results. During the periods presented, the Company reported its financial performance based on the following segments: Contract Manufacturing and Other Business Lines.

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The international sales, concentrated primarily in Europe, for the fiscal years ended* June 30, 2026and2025* were $8,640 and $10,726, respectively.

-49-

Financial information relating to the fiscal years ended* June 30, 2026and2025* operations by business segment are as follows:

-50-

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.

-51-